<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04251780</url>
  </required_header>
  <id_info>
    <org_study_id>ConnK+</org_study_id>
    <nct_id>NCT04251780</nct_id>
  </id_info>
  <brief_title>Tissue K+ in Primary Hyperaldosteronism</brief_title>
  <official_title>Changes in Tissue Potassium Amount Before and After Treatment of Primary Hyperaldosteronism Assessed by 39K-MRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Erlangen-Nürnberg Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Erlangen-Nürnberg Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent human studies found tissue sodium storage in patients with hyperaldosteronism that
      could be detected non-invasively by 23Na-MRI. Tissue sodium accumulation could be mobilized
      upon treatment of hyperaldosteronism. Besides, former animal studies applying chemical
      electrolyte analysis indicate that this aldosterone induced sodium storage might be
      accompanied by intracellular potassium loss. Wether such an intracellular tissue Potassium
      loss occurs in vivo in patients with hyperaldosteronism and if this deficiency can be
      corrected by treatment is unclear. The investigators will employ 39K-MR Imaging at 7Tesla to
      further assess this hypothesis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients diagnosed with primary hyperaldosteronism will be investigated using 23Na-MRI and
      39K-MRI at 7 Tesla to assess tissue sodium and potassium content. Measurements will be
      conducted before treatment of hyperaldosteronism and three months after adrenal surgery or
      medical treatment (Spironolactone or Eplerenone). Furthermore, blood pressure, body water
      distribution (by bioimpedance spectroscopy), serum electrolytes as well as monocyte function
      will be assessed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Imaging Assessment before and after treatment</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tissue potassium content</measure>
    <time_frame>3-6 months after intervention</time_frame>
    <description>Change in tissue potassium content measured by MRI before and after treatment of hyperaldosteronism</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>3-6 months after intervention</time_frame>
    <description>Change in blood pressure (systolic/diastolic/mean) before and after treatment of hyperaldosteronism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue sodium content</measure>
    <time_frame>3-6 months after intervention</time_frame>
    <description>Change in tissue sodium content measured by MRI before and after treatment of hyperaldosteronism</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Primary Hyperaldosteronism</condition>
  <condition>Electrolyte Disturbance</condition>
  <arm_group>
    <arm_group_label>Hyperaldosteronism treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with Hyperaldosteronism will either be treated by adrenalectomy (adrenal adenoma) or receive medical treatment (Spironolactone/Eplerenone; bilateral hyperplasia) as indicated by the Endocrinological Guideline (J Clin Endocrinol Metab, May 2016). Before and after intervention tissue sodium and tissue potassium amount will be assessed by MRI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical Treatment of Hyperaldosteronism</intervention_name>
    <description>Surgery of an Aldosterone-producing adenoma</description>
    <arm_group_label>Hyperaldosteronism treatment</arm_group_label>
    <other_name>Adrenalectomy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug treatment of Hyperaldosteronism</intervention_name>
    <description>Treatment of Hyperaldosteronism with Spironolactone or Eplerenone.</description>
    <arm_group_label>Hyperaldosteronism treatment</arm_group_label>
    <other_name>Medication</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Primary Hyperaldosteronism diagnosed according to the endocrinological guidelines (J Clin
        Endocrinol Metab, May 2016)

        Exclusion Criteria:

          -  Chronic kidney disease stage 3b and below (estimated GFR &lt;30 ml/min according to
             CKD-EPI)

          -  Acute kidney injury

          -  Severe congestive heart failure (NYHA III and IV)

          -  Liver Cirrhosis (Child B and C)

          -  Pregnancy

          -  Contraindications for MRI measurements: cardiac Pacemaker, claustrophobia, etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Kopp, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nephrology Department, University Erlangen-Nurnberg, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christoph Kopp, MD</last_name>
    <phone>+4991318539002</phone>
    <email>christoph.kopp@uk-erlangen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Armin Nagel, PhD</last_name>
    <phone>+4991318525900</phone>
    <email>armin.nagel@uk-erlangen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nephrology Department, University Hospital Erlangen</name>
      <address>
        <city>Erlangen</city>
        <state>Bavaria</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Kopp, MD</last_name>
      <phone>0049 9131 8539002</phone>
      <email>christoph.kopp@uk-erlangen.de</email>
    </contact>
    <contact_backup>
      <last_name>Anke Dahlmann, MD</last_name>
      <phone>0049 9131 8539002</phone>
      <email>anke.dahlmann@uk-erlangen.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Radiology Department, University Hospital Erlangen</name>
      <address>
        <city>Erlangen</city>
        <state>Bavaria</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armin Nagel, PhD</last_name>
      <phone>+4991318525900</phone>
      <email>armin.nagel@uk-erlangen.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Kopp C, Linz P, Wachsmuth L, Dahlmann A, Horbach T, Schöfl C, Renz W, Santoro D, Niendorf T, Müller DN, Neininger M, Cavallaro A, Eckardt KU, Schmieder RE, Luft FC, Uder M, Titze J. (23)Na magnetic resonance imaging of tissue sodium. Hypertension. 2012 Jan;59(1):167-72. doi: 10.1161/HYPERTENSIONAHA.111.183517. Epub 2011 Dec 5.</citation>
    <PMID>22146510</PMID>
  </results_reference>
  <results_reference>
    <citation>Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young WF Jr. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016 May;101(5):1889-916. doi: 10.1210/jc.2015-4061. Epub 2016 Mar 2.</citation>
    <PMID>26934393</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 30, 2020</study_first_submitted>
  <study_first_submitted_qc>January 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>February 3, 2020</last_update_submitted>
  <last_update_submitted_qc>February 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperaldosteronism</keyword>
  <keyword>Potassium</keyword>
  <keyword>Magnetic Resonance Imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperaldosteronism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

